Welcome to our dedicated page for HeartSciences news (Ticker: HSCSW), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.
HeartSciences Inc. develops healthcare information technology for ECG/EKG management and AI-enabled cardiac analysis. News about the company centers on commercialization of MyoVista Insights, a cloud-native, device-agnostic ECG management and analysis platform, and MyoVista wavECG, a device designed to provide conventional ECG functionality while supporting AI-enabled solutions.
Recurring updates include platform interoperability, hospital and academic adoption, customer and reference-site activity, FDA-related developments for MyoVista wavECG, and quarterly financial and business updates. Company announcements also cover EHR workflow integration, ECG data management, clinical decision-support features, and investor communications tied to its Nasdaq-listed common stock and warrants.
Heart Test Laboratories, operating as HeartSciences (NASDAQ: HSCS), announced its participation in the inauguration of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital on September 14, 2022. The facility aims to enhance cardiology through advanced technologies including AI. HeartSciences seeks to improve ECG diagnostic capabilities with its MyoVista device, which detects left ventricular diastolic dysfunction. This collaboration supports their FDA pivotal validation study and aligns with the hospital's commitment to innovative healthcare solutions.
Heart Test Laboratories, operating as HeartSciences (NASDAQ: HSCS; HSCSW), announced that CEO Andrew Simpson will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. The presentation will be available for on-demand viewing starting September 12 at 7:00 AM ET. HeartSciences focuses on enhancing ECG technology with AI to improve cardiac dysfunction detection, specifically through its MyoVista device, which aims for FDA clearance. For more details, visit www.heartsciences.com.